Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Valion Bio (TIVC) Return on Capital Employed (2022 - 2025)

Valion Bio has reported Return on Capital Employed over the past 4 years, most recently at 156.56% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 2545.0% year-over-year to 156.56%; the TTM value through Sep 2025 reached 156.56%, up 2545.0%, while the annual FY2024 figure was 152.59%, 4778.0% up from the prior year.
  • Return on Capital Employed for Q3 2025 was 156.56% at Valion Bio, up from 191.3% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 53.39% in Q1 2022 and troughed at 235.64% in Q1 2024.
  • A 4-year average of 173.62% and a median of 191.3% in 2025 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: crashed -14954bps in 2023 and later soared 2545bps in 2025.
  • Year by year, Return on Capital Employed stood at 195.58% in 2022, then increased by 10bps to 176.14% in 2023, then decreased by -14bps to 200.14% in 2024, then grew by 22bps to 156.56% in 2025.
  • Business Quant data shows Return on Capital Employed for TIVC at 156.56% in Q3 2025, 191.3% in Q2 2025, and 222.89% in Q1 2025.